Nicotinamide decreases MHC class II but not MHC class I expression and increases intercellular adhesion molecule-1 structures in non-obese diabetic mouse pancreas

G Papaccio1, E Ammendola1 and F A Pisanti2,3

1Institute of Histology, Second University of Naples, Naples, Italy
2Department of Clinical Pathology, ASL NA4, 80044 Ottaviano, Naples, Italy
3Department of Cell Biology, University of Calabria, Cosenza, Italy

(Requests for offprints should be addressed to G Papaccio, 21 via Giuseppe Bonito, 80129 Napoli, Italy)

Abstract

Pancreases of untreated and nicotinamide (NIC)-treated pre-diabetic (10-week-old) and overtly diabetic (25-week-old) female NOD (non-obese diabetic) mice and of NON (non-obese non-diabetic) control mice were studied, with the following results.

(1) Islets and ducts of overtly diabetic untreated NOD mice (25-week-old) were found to express low levels of MHC class I and II molecules, like NON controls, and high levels of adhesive molecules. (2) NIC was able to slightly affect glycaemia and insulin, slowing down diabetes progression. Moreover it significantly decreased MHC class II expression (but not class I) in vivo by week 10, and significantly enhanced intercellular adhesion molecule-1 (ICAM-1) expression, mainly by week 25, within the pancreas, where 5-bromo-2'-deoxyuridine positive nuclei and insulin positive cells were present, demonstrating that a stimulation of endocrine cell proliferation occurs. (3) In addition, NIC partly counteracted the fall of superoxide dismutase levels, observed in untreated diabetic NOD animals. (4) In vitro studies demonstrated that NIC: (i) was able to significantly reduce nitrite accumulation and to increase NAD+NADH content significantly, and (ii) was able to increase the levels of interleukin-4, a T helper 2 lymphocyte (Th2) protective cytokine, and of interferon-α (IFN-α), which is known to be able to induce MHC class I and ICAM-1 but not MHC class II expression, as well as IFN-γ, which is also known to be able to induce MHC class I and ICAM-1 expression. The latter, although known to be a proinflammatory Th1 cytokine, has also recently been found to exert an anti-diabetogenic role.

This study therefore clearly shows that adhesive mechanisms are ongoing during the later periods of diabetes in pancreatic ducts of NOD mice, and suggests they may be involved in a persistence of the immune mechanisms of recognition, adhesion and cytolysis and/or endocrine regeneration or differentiation processes, as both NIC-increased ICAM-1 expression and 5-bromo-2'-deoxyuridine positivity imply. The effects of NIC on MHC class II (i.e. a reduction) but not class I, and, mainly, on ICAM-1 expression (i.e. an increase), together with the increase in Th2 protective cytokine levels are very interesting, and could help to explain its mechanism of action and the reasons for alternate success or failure in protecting against type 1 diabetes development.


Introduction

Infiltration by mononuclear cells around and within pancreatic islets is the first morphological evidence of type 1 diabetes. In animal models such as the NOD (non-obese diabetic) mouse, infiltration, especially during the early stages of the disease, is not limited to the islets, but involves the whole pancreas, and its ducts in particular (Papaccio et al. 1993a). Moreover, in addition to the pancreas, infiltration affects other organs such as the thyroid (Asamoto et al. 1984), adrenals (Asamoto et al. 1984), salivary glands (Miyagawa et al. 1986) and Harderian glands (Papaccio et al. 1996).

Immunocytochemical studies in animal models demonstrate that infiltrating cells within and around the islets are Ia-b (class II) immunoreactive cells (Papaccio et al. 1991, 1993b), and that an MHC class II immunoreactivity is expressed on endothelia in diabetic rats (Bretzel et al. 1990). Nicotinamide (NIC), an inhibitor of poly ADP ribose synthetase, thought to be protective for islet β cells in NOD mice (Yamada et al. 1982), has been shown to inhibit class II but not class I expression in mouse islet cells in culture (Yamada et al. 1990).

Several adhesion molecules participate in various immune responses and have been shown to be involved in the pathogenesis of autoimmune diseases. Intercellular
adhesion molecule-1 (ICAM-1) is a well-characterized surface glycoprotein belonging to the immunoglobulin superfamily. The ICAM-1 molecule has been shown to be involved in various leukocyte functions, including T-cell differentiation, antigen presentation and extravasation into lymphoid and inflamed non-lymphoid tissues (Dustin et al. 1986, 1988, Springer 1990). In addition, expression of ICAM-1 can be induced on a variety of cells at the site of inflammation by cytokines; ICAM-1 is also involved in recognition, adhesion and cytolysis by killer lymphocytes (Dustin et al. 1986, Makgoba et al. 1988). An increased expression of adhesion molecules has been described in the diabetic human pancreas, mainly on endothelial cells (Hänninen et al. 1992). In the NOD mouse, MHC class II and ICAM-1 immunoreactivities have been observed in pancreatic endothelial cells (Linn et al. 1994) and around pancreatic ducts in pre-diabetic animals (Papaccio et al. 1995).

Expression of ICAM-1 has recently been observed on NOD pancreatic islet β cells (Yagi et al. 1995). This phenomenon, induced by inflammatory cytokines, seems to facilitate the destruction of islet β cells by CD8 cytotoxic lymphocytes (CTL). While ICAM-1 expression on vascular endothelium and on pancreatic islet β cells has been partly explained, its significance at the level of pancreatic ducts seems to be rather more complex. Tissue non-specific cellular adhesion molecules (CAMs) have been interpreted as co-stimulatory molecules in the ‘local’ immune response (Yang et al. 1996). It has also been shown that both interferon-α (IFN-α) and IFN-γ are able to induce MHC class I and ICAM-1, but not MHC class II, expression (Chakrabarti et al. 1996). On the other hand, anti-ICAM-1 treatment has been shown to induce tolerance (Isobe et al. 1992), and ICAM-1 expression in inflamed islets during disease progression up to 17 weeks of age does not appear to be modified (Yang et al. 1996). Therefore, ICAM-1 expression and its interactions with leucocyte-function-associated antigen-1 (LFA-1) seem to be not only as important as other CAM (namely L-selectins) pathways in the control of tissue-selective lymphocyte homing, but also in other poorly known phenomena such as specific cell–cell interactions in embryogenesis and histogenesis.

NIC has been shown to stimulate cell replication (Sandler & Anderson 1988), to form islet-like cell clusters (Sandler et al. 1989) and to be a potent inducer of endocrine differentiation in cultured human fetal pancreatic cells (Otontoski et al. 1993). In the majority of these instances pancreatic ducts are involved in regeneration, and their role in this process in the adult pancreas has been reconsidered recently (Bonner-Weir et al. 1993, Wang et al. 1995). Like NIC, superoxide dismutase (SOD)–polyethylene glycol has been shown to moderately suppress the induction of class II molecules (Yamada et al. 1993). This shows indirectly that hydroxyl radicals may also play a role in class II antigen expression.

In view of these findings, our aim was to investigate islet and pancreatic duct MHC class I, II and ICAM-1 molecule expression, as well as the cytokine profile, both in untreated and NIC-treated pre-diabetic and overtly diabetic NOD mice, in order to define better their significance, relevance, time of appearance and role.

**Materials and Methods**

**Animals**

Five-week-old (n=30) female NOD mice (purchased from Bontmice, Bonholtgarten, Denmark) were used for the experiment. In this colony, clinically evident diabetes is observable by week 22 in 90–100% of females but in less than 20% of males. The first histopathological lesion is peri-vasculitis, seen by week 5. Peri-insultis and peri-ductulitis are present by weeks 8–10; by week 15 insulin is massive.

**In vivo experiments**

Animals, free from viral or bacterial infections, and weighing 20–35 g, were not subjected to insulin treatment. Twenty mice were treated with a 10% aqueous solution of NIC (Sigma, Milan, Italy) at a dose of 0.5 mg/g body weight/day i.p. from week 5 (non-diabetic insulin-resistant free period) to week 20 (pre-clinical diabetic period). The remaining animals (n=10) were untreated (NOD untreated controls).

Animals were anaesthetized with ether and the pancreases removed for morphological evaluation at week 10 or 25. These time-points were chosen because at week 10 insulinitis is already present and at week 25 animals are overtly diabetic. The NON (non-obese non-diabetic) mouse is another albino strain obtained by Dr M Hattori (Joslin Diabetes Center, Boston, MA, USA), which is a diabetes-resistant control strain containing a diabetes-resistant gene. Twenty females of this strain and of the same age were used as non-diabetic controls. Half of them (n=10) were treated with NIC, as described above, and the remainder were untreated. For islet cell culture, untreated 10-week-old NOD and NON animals (n=15 per group) were used (see below). For in vivo labelling of proliferating cells, NOD and NON animals, both NIC-treated and untreated (n=5 per group), were used (see below).

**Glycaemia**

Blood glucose levels were tested weekly using the hexokinase method (Boehringer, Mannheim, Germany). Animals were considered hyperglycaemic when their non-fasting blood glucose levels were higher than...
8 mmol/l but lower than 12 mmol/l at two successive determinations. Mice were considered diabetic when their blood glucose levels exceeded 12 mmol/l.

**Standard light microscopy**

Pancreatic samples from each animal were fixed with Bouin’s fixative and embedded in paraffin. Specimens were sectioned serially (5 µm thick) and stained with haematoxylin–eosin or Gomori aldehyde fuchs in for general morphology, and for the evaluation of islet and extra-islet infiltration.

**Immunocytochemistry**

Samples from the tail of each pancreas were collected and kept frozen in liquid nitrogen. Randomly selected cryocut sections were stained by the avidin–biotin peroxidase indirect staining method as previously described (Papaccio et al. 1991). At least 30 ducts and islets per pancreas were observed.

The monoclonal antibodies used in this experiment were: anti-MHC class I (HLA-ABC; Dakopatts, Milan, Italy), anti-MHC class II (Ia-b HLA-DR β chain, IgG1; Dakopatts), anti-ICAM-1 rat anti-mouse (CD45; clone 84H10; Dakopatts), anti-T lymphocyte antibodies (Dakopatts), including CD4 (MT310) and CD8 (DK24), anti-macrophage antibody BM8, which detects murine pan macrophages (BMA Biomedicals AG, Augst, Switzerland), anti-insulin, anti-glucagon and anti-somatostatin antibodies (Dakopatts). Secondary antibody was biotinylated goat anti-rat (Dakopatts). As the negative control, the primary antibody was substituted with rat non-immune serum.

Sections 5 µm thick were observed for semi-quantitative analysis. The immunoreactive elements on alternate sections were determined at a magnification of ×400 using an eyepiece with a square-ruled grid with a total area of 0.062 mm² and counted with an M4 image analysis system (Imaging, Brock University, St Catherines, Ontario, Canada) in different areas. This allowed the calculation of immunoreactive cells per mm² ± S.E.M.

**In vivo labelling for proliferating cells**

In vivo pulse labelling with 5-bromo-2’-deoxyuridine (BrdU) (Sigma), a thymidine analogue, and immunostaining of the incorporated BrdU were used to mark the cells that had synthesized DNA during the incubation period. Ten hours before killing, BrdU (100 mg/kg body weight, freshly dissolved in PBS) was injected i.p. into 25-week-old untreated (n=5) and NIC-treated (week 5 and week 20) (n=5) NOD mice and NON controls (n=5 per group). The number of immunostained nuclei was quantified. At least ten ducts per pancreas were viewed. Detection of granule-containing endocrine cells was accomplished with anti-insulin antibody. For double labelling to BrdU and insulin, deparaffinized sections were washed first in hydrochloric acid (0.5 mol/l, 10 min), followed by incubation with primary anti-BrdU antibody (Dakopatts). Sections were then incubated overnight (4°C) with the second primary antibody to insulin.

**SOD assay**

Total SOD activity, as well as Cu-Zn SOD and Mn SOD in extracts, was measured by the xanthine/xanthine oxidase, cytochrome C reduction method (McCord & Fridovich 1969) and values were expressed as U/mg protein.

**Islet cell culture**

Pancreatic islets were isolated by digestion with collagenase type IV (Sigma) from untreated 10-week-old NOD and NON (n=15 per group) mice (Brunstedt et al. 1984). After isolation, islets were pre-cultured for 3–7 days in RPMI 1640 (Sigma) supplemented with 10% fetal calf serum at 37°C in humidified atmospheric air. Then, 150 islets/300 µl medium were incubated for 24 h in RPMI 1640 supplemented with 0.2% BSA, with or without 10 or 20 mmol/l NIC, and the culture was continued for 6 days, with the medium being changed after 3 days.

**NAD+NADH and nitrite accumulations**

The media were taken for assessment of accumulated nitrite concentrations (see below). Groups of 50–100 islets were incubated for 60 min in plastic tubes containing 100 µl Krebs–Ringer bicarbonate buffer and then retrieved for NAD+NADH determination (Strandell et al. 1988).

For the nitrite assay, culture media samples (150 µl) were mixed with an equal volume of the Griess reagent (1 part 0.1% naphthylethylene diamine dihydrochloride and 1 part 1% sulphanilamide in 5% H₃PO₄) and incubated for 10 min at room temperature (Green et al. 1982). The absorbance at 550 nm was measured and the concentration of nitrite was determined by means of a sodium nitrite standard curve. The detection limit was 1 µmol/l, corresponding with 2 pmol/islet in our experiment.

**Cytokine profile**

Groups of islets (500 per dish), cultured as above described, were harvested by pipetting, centrifuged to a pellet (200 g, 2 min), the supernatant removed, and used for measurement of interleukin–2 (IL–2), IL–4, IFN–γ, IFN–α or tumour necrosis factor–α (TNF–α) levels following centrifugation for 5 min at 2000 r.p.m. to eliminate cell debris. The concentrations of IL–2, IL–4, IFN–γ, IFN–α and TNF–α were measured by ELISA using monoclonal
antibodies specific for IL-2, IL-4, IFN-γ, IFN-α and TNF-α (Openshaw et al. 1995). The amount of cytokine present was determined from the standard curves from purified recombinant cytokines. Values are expressed as U/ml.

Statistical evaluation

Student’s t-test was used for statistical analysis and the level of significance was set at $P<0.05$. Groups of data were analyzed by ANOVA, followed either by Fisher’s test or Student’s t-test. When Student’s paired t-test was used, $P$ values were corrected for multiple comparisons using the Bonferroni method (Wallenstein et al. 1980). Data are given as means ± s.d.

Results

NIC affects glycaemia slowing down diabetes progression

Blood glucose levels are shown in Fig. 1. The mean ± s.d. non-fasting blood glucose level at week 10 was found to be $4.2 ± 0.3$ mmol/l for untreated NOD, $4.3 ± 0.7$ for NIC-treated NOD, $4.6 ± 0.6$ for untreated NON controls and $4.5 ± 0.6$ for NIC-treated NON controls. These animals, therefore, were considered to be normoglycaemic. The mean value for 25-week-old untreated NOD mice was $19.2 ± 2.6$ mmol/l ($P<0.0001$ vs week 10), with $11.0 ± 2.5$ for NIC-treated NOD animals ($P<0.001$ vs week 10). In the latter group (NIC-treated NOD animals), 9/15 mice showed values exceeding $12$ mmol/l and the remaining 6/15 animals showed values which were still less than $12$ mmol/l. Therefore, the untreated NOD animals were considered to be overtly diabetic, along with 9/15 NIC-treated NOD mice, while the remaining 6/15 NIC-treated NOD animals were considered to be hyperglycaemic but not overtly diabetic.

Control NON mice (both untreated and NIC-treated) at week 25 were always normoglycaemic (with values of $4.8 ± 0.5$ and $4.9 ± 0.8$ mmol/l respectively).

NIC partly affects insulitis progression

Control NON (untreated and NIC-treated) mice always had normal islets and ducts, and no signs of infiltration were observed.

Untreated 10-week-old NOD mice showed clear signs of infiltration by mononuclear cells. Infiltrating cells (mainly monocytes/macrophages) were observed within small post-capillary vessels or in perivascular areas surrounding non-islet ducts, within the connective tissue of these ducts and within the epithelial layer.

Diabetic 25-week-old untreated NOD mice only occasionally showed signs of insulitis. Islets were mostly
Table 1 Quantitative evaluation of pancreatic duct positive cells in untreated and NIC-treated NOD and NON control mice. Data are given as positive cells/mm² ± S.E.M. The table shows that 25-week-old NOD-NIC-treated animals still expressed high amounts of ICAM-1 structures but that they did not express significant amounts of MHC class I and II molecules. NIC treatment significantly decreased MHC class II (but not class I) expression and significantly enhanced ICAM-1 expression both in NOD and NON animals

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Strain</th>
<th>Week 10 Untreated</th>
<th>Week 10 NIC-treated</th>
<th>Week 25 Untreated</th>
<th>Week 25 NIC-treated</th>
</tr>
</thead>
<tbody>
<tr>
<td>MHC class I</td>
<td>NOD</td>
<td>14 ± 3</td>
<td>15 ± 4</td>
<td>1 ± 0.2</td>
<td>2 ± 1</td>
</tr>
<tr>
<td></td>
<td>NON</td>
<td>1 ± 0.2</td>
<td>3 ± 0.6</td>
<td>1 ± 0.2</td>
<td>2 ± 0.6</td>
</tr>
<tr>
<td>MHC class II</td>
<td>NOD</td>
<td>17 ± 1.0&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>7 ± 2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3 ± 0.5</td>
<td>1 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>NON</td>
<td>1 ± 0.2</td>
<td>1 ± 0.1</td>
<td>1 ± 0.5</td>
<td>1 ± 0.2</td>
</tr>
<tr>
<td>ICAM-I</td>
<td>NOD</td>
<td>10 ± 0.5</td>
<td>13 ± 2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>3 ± 0.5</td>
<td>13 ± 3&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>NON</td>
<td>–</td>
<td>4 ± 1</td>
<td>–</td>
<td>4 ± 1</td>
</tr>
<tr>
<td>BM8</td>
<td>NOD</td>
<td>3 ± 0.1</td>
<td>3 ± 0.1</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>NON</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CD4</td>
<td>NOD</td>
<td>–</td>
<td>–</td>
<td>2 ± 0.2</td>
<td>3 ± 0.5</td>
</tr>
<tr>
<td></td>
<td>NON</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CD8</td>
<td>NOD</td>
<td>2 ± 0.1</td>
<td>3 ± 0.1</td>
<td>1 ± 0.1</td>
<td>4 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>NON</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

<sup>a</sup><i>P</i>&lt;0·001 vs 25-week-old NOD mice and vs NON controls; <sup>b</sup><i>P</i>&lt;0·001 vs week 10 NIC-treated animals; <sup>c</sup><i>P</i>&lt;0·01 vs MHC class II week 10 NIC-treated animals; <sup>d</sup><i>P</i>&lt;0·0001 vs week 25 untreated animals (Student’s t-test).

Nicotinamide in NOD mice · G PAPACCIO and others

small (atrophic or retracted with evident signs of cyto-architectural derangement). The ducts were also devoid of infiltration and showed no signs of destruction.

NIC treatment in NOD mice slightly affected the progression of insulitis, which showed a less severe progression of inflammation. The findings observed at week 10 were quite similar to those observed in untreated NOD pancreas. Several islets were still infiltrated (showing an intra-islet infiltration) at week 25, when the islets and ducts were also surrounded by mononuclear cells in 6/15 animals (the same animals showed less severe hyperglycaemia). Evident signs of islet atrophy and of cyto-architectural derangement were observed in 9/15 animals which were also overtly diabetic.

NIC decreases MHC class II, but not class I, and increases ICAM-1 expression

Semi-quantitative evaluations are summarized in Table 1. Untreated 10-week-old NOD mice showed both MHC class I and class II (Ia-b) molecules within the whole pancreas. Positivity for MHC class I and II structures was significantly higher with respect to that for ICAM-1 structures (<i>P</i>&lt;0·001). Positivity for MHC class I and, mainly, for class II molecules (Fig. 2a) was observed within the connective tissue surrounding the ducts (mainly infiltrating cells), and was different from that reported in our previous work in 8-week-old NOD mice (Papaccio et al. 1995) at the level of the epithelial layer of the ducts. Often the whole epithelial layer was positive for Ia-b (Fig. 2a) as well as ICAM-1 molecules (Fig. 2b). For islet ducts this positivity extended to the islets. ICAM-1 structures were often observed in groups on cells of the connective layer surrounding the ducts and on their epithelial cells (Fig. 2b). No differences were observed among the animals. ICAM-1 immunoreactive structures also were observed on islet cells and on scattered cells, mainly along septa, within the pancreas (Fig. 2b).

CD8<sup>+</sup> (lymphocyte) and BM8<sup>+</sup> (macrophage) cells were observed only among scattered cells of ducts, either in the connective layer or within the epithelial cell layer (Fig. 2c). BM8<sup>+</sup> cells were considerably fewer in number, when compared with the MHC class I, II and ICAM-1 positive cells (<i>P</i>&lt;0·001). In particular, one could observe that while MHC class I and II (Ia-b) and ICAM-1 structures clearly were expressed by epithelial cells of the ducts, BM8 or CD8 structures were expressed only by infiltrating cells located either in the connective layer or in between epithelial cells. Occasionally, isolated insulin positive cells were seen along ducts.

Positivity for insulin, glucagon and somatostatin was normal within islets, where a CD8 positivity was also present.

In 25-week-old untreated diabetic NOD animals, MHC class I and II molecules were only rarely observed on islets and pancreatic ducts, but ICAM-1 expression (Fig. 2d) was, unexpectedly, still observable; these structures were decreased when compared with those observed in 10-week-old animals but were more abundant than MHC class I and II molecules found in animals of the same age (<i>P</i>&lt;0·001). Islets only showed rare insulin positive cells but showed a normal pattern for glucagon and...
Figure 2 (a) Light micrograph of an untreated 10-week-old NOD mouse pancreas showing Ia-b⁺ epithelial cells of a duct (arrows). The whole epithelial layer expresses Ia-b⁺ molecules on the lateral and basal portions of these cells (original magnification × 300). (b) Light micrograph of an untreated 10-week-old NOD mouse pancreas showing BM8⁺ (macrophage) cells (large arrow), scattered within the connective layer, surrounding the duct, and BM8⁺ isolated cells within the epithelial layer of the duct (small arrows) (original magnification × 300). (c) Light micrograph of an untreated 10-week-old NOD mouse pancreas showing ICAM-1⁺ structures located both at the level of the connective layer (large arrows) and at the epithelial layer (small arrows) of a duct. Positivity seems to involve a consistent number of these cells. Several cells along septa (arrowheads) are also ICAM-1⁺ (original magnification × 300). (d) Light micrograph of an untreated 25-week-old NOD mouse pancreas showing ICAM-1⁺ cells of a duct (small arrows). ICAM-1⁺ structures are also visible at the level of the connective layer (large arrows) (original magnification × 300).
somatostatin positive cells. CD8 and BM8 structures were not observed on ducts or in islets, and only a few CD4+ cells were observed.

NIC-treated 10-week-old NOD females showed a significantly lower expression of Ia-b molecules, but not of MHC class I structures (which were of comparable intensity with respect to untreated controls), and a significant increase in ICAM-1 molecules compared with those found in untreated NOD animals (P<0.001). This increased expression, paralleled by a decrease in MHC class II expression (but not that of class I) in 10-week-old animals was observed in the whole pancreas and involved the infiltrate in all the animals (Fig. 3a), although in 25-week-old animals it was

Figure 3  (a) Light micrograph of a 10-week-old NOD animal treated with NIC. ICAM-1 expression involves the infiltrate (arrows) (original magnification × 300). (b) Light micrograph of a 25-week-old NOD animal treated with NIC. ICAM-1 expression is clearly seen at the level of ductal cells (large arrows) as well as within the connective tissue (small arrows) (original magnification × 300). (c) Light micrograph of a 25-week-old NON animal untreated with NIC showing no positivity for ICAM-1 molecules (original magnification × 300). (d) Light micrograph of a 25-week-old NOD animal treated with NIC. Single-staining for insulin (small arrows) and BrdU (large arrow), and double-stained cells (arrowhead) for the same antibodies are seen (original magnification × 300).
primarily observable on ducts and in small clusters within the pancreas (Fig. 3b). BM8+ cells were observed only rarely.

Control untreated NON mice showed a weak MHC class I and II positivity, and were completely negative for ICAM-1, lymphocyte and macrophage antibodies (Fig. 3c). NIC-treated NON animals did show an increased expression of MHC class I and, particularly, of ICAM-1 structures, although only by a small amount when compared with that observed in NIC-treated NOD animals.

NIC stimulates endocrine cell proliferation

Only NIC-treated NOD animals showed a clear BrdU positivity in some ductal cell nuclei and in nuclei within pancreatic acini (Fig. 3d). Double-staining for insulin confirmed their endocrine nature (β cells). The frequency of endocrine insulin-containing β cells intercalated in the duct epithelium increased with age in all evaluated animals. The in vivo labelling of cells synthesizing DNA showed a relative expansion of the ductal epithelium, i.e. an attempt at proliferation. BrdU positive nuclei were seen in common pancreatic ducts as well as in focal regions of pancreatic acini (scattered cells). The average number of BrdU positive nuclei counted per pancreas in NIC-treated NOD animals was 280 ± 30, and the average number of BrdU and insulin co-stained cells was 95 ± 15 per pancreas.

NIC partly counteracts the SOD activity fall observed in diabetic NOD animals

Results are shown in Table 2. Untreated NOD mice showed very low levels of total SOD and, in particular, of Cu-Zn SOD, the values of which decreased to extremely low amounts in 25-week-old untreated NOD animals (P<0.0001 vs NON). NIC counteracted this fall significantly (P<0.001) in NOD animals; the increase in values was significant when compared with untreated diabetic animals (P<0.001). It was still a very low amount when compared with values found in NON untreated animals (P<0.0001). NIC also raised total SOD values in NON mice (P<0.01 vs untreated NON).

NIC increases NAD+NADH and decreases medium nitrite contents

Values are shown in Table 3. NAD+NADH content (expressed as pmol/10 islets) was increased significantly after exposure to NIC (P<0.001 vs values for untreated controls).

Cultured islets of untreated female NOD mice accumulated significant amounts of nitrite, but NIC added to the medium was able to decrease medium nitrite contents (see Table 2). The lower dose (NIC 10 mmol/l) in particular was more effective at decreasing the nitrite content (P<0.0001 vs untreated NOD), thus suggesting the existence of a dose-dependent response.

NIC increases levels of a T helper 2 lymphocyte (Th2) protective cytokine IL-4 as well as IFN-α and IFN-γ

NIC-treated islets from NOD mice showed high levels of IFN-α (P<0.001 vs NON) as well as IL-4 (P<0.001 vs NON) production (Fig. 4). In particular, islets treated with higher amounts of NIC (20 mmol/l) showed the highest levels of IFN-α (P<0.001 vs NOD-NIC 10 mmol/l) and IL-4 (P<0.01 vs NON-NIC 10 mmol/l), as well as of IFN-γ (P<0.001 vs NON and NOD-NIC).

Table 2 SOD levels in NOD and NON untreated and NIC-treated animals. Data expressed as U/mg protein, are means ± S.D.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Week 10</th>
<th>Week 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>T. SOD</td>
<td>Cu-Zn SOD</td>
<td>Mn-SOD</td>
</tr>
<tr>
<td>NON-untreated</td>
<td>160 ± 22</td>
<td>125 ± 15</td>
</tr>
<tr>
<td>NON-NIC</td>
<td>175 ± 35</td>
<td>135 ± 25</td>
</tr>
<tr>
<td>NOD-untreated</td>
<td>9 ± 2.0</td>
<td>6.5 ± 1</td>
</tr>
<tr>
<td>NOD-NIC</td>
<td>17 ± 3</td>
<td>13 ± 2</td>
</tr>
</tbody>
</table>

Untreated NOD mice showed very low levels of total (T.) SOD and of Cu-Zn SOD (P<0.0001 vs NON at week 25). NIC-treated animals showed significantly (P<0.001) increased values. NIC also raised total SOD values in NON mice (P<0.01 vs untreated NON). Anova and Students’s t-test were used for statistical analysis.
10 mmol/l). Control untreated islets from diabetic NOD animals showed high levels of TNF-α (P<0.001 vs NON and NOD-NIC) and IL-2 (P<0.001 vs NON and NOD-NIC) cytokines (Fig. 4). Moreover, islets from diabetic NOD animals showed high levels of IFN-γ (P<0.001 vs NON), though their levels were significantly lower with respect to those observed in NIC-treated NOD-10 mmol/l and IFN-γ (P<0.001 vs NON and NOD-NIC-10 mmol/l) levels. Untreated NOD islets showed high levels of TNF-α (P<0.001 vs NON and NOD-NIC) and IL-2 (P<0.001 vs NON and all NON-NIC groups) cytokines. Untreated NOD animals showed high levels of IFN-γ (P<0.001 vs NON and NOD-NIC-10 mmol/l). Student’s t-test followed by Bonferroni method was used for statistical analysis.

**Discussion**

The present study demonstrates the following facts. (1) MHC class I and II and ICAM-1 structures are expressed not only at the level of the connective layer of the ducts, as previously shown in 8-week-old animals (Papaccio et al. 1995), but also are clearly observable at the level of epithelial cells lining the ducts in 10-week-old mice. (2) Adhesive molecules are still expressed mainly at the ductal level in 25-week-old diabetic animals, but they do not express significant amounts of MHC class I and II molecules. (3) CD8+ and BM8+ cells are the prevailing infiltrating elements in pre-diabetic ducts. CD4+ cells, while extremely scarce, are the only infiltrating cells still present in overtly diabetic animals. (4) NIC affects glycocaemia and insulitis in animals showing a less severe progression of diabetes. Moreover, it significantly decreases MHC class II, but not class I, expression and significantly enhances ICAM-1 molecules. In 25-week-old animals, these structures are particularly increased on ducts and on small clusters of cells within the exocrine pancreas, where BrdU positive nuclei are also present, although as a small percentage. (5) The co-staining for BrdU and insulin may suggest that insulin-co-staining β cells try to proliferate after NIC treatment. (6) NIC is able to significantly counteract the fall in SOD levels observed in diabetic NOD animals and, in particular, Cu–Zn SOD values, which are most affected by diabetes progression in the NOD mouse. (7) In vitro studies show that NIC significantly reduces medium nitrite accumulation after 6 days of culture, and is capable of increasing

![Figure 4](image-url)
NAD+NADH content. Moreover, it is able to significantly increase the levels of IL-4, a protective Th2 cytokine, as well as the proinflammatory IFN-α and IFN-γ cytokines. In fact, NIC-treated islets from NOD mice show high levels of IL-4 production and, in particular, islets treated using higher amounts of NIC show the highest levels of IL-4, IFN-α and IFN-γ. Conversely, control untreated islets from diabetic animals show high levels of TNF-α and IL-2, both Th1 destructive cytokines.

The expression of the proinflammatory Th1 cytokines IL-2 and TNF-α predicts β cell destruction in diabetic untreated NOD islets, whereas increased expression of Th2 cytokine IL-4 is protective. Therefore, NIC seems to be able to significantly increase the levels of a protective Th2 cytokine, and also of IFN-α, which is known to be able to induce MHC class I and ICAM-1 but not MHC class II molecules (Chakrabarti et al. 1996). On the other hand, although IFN-α is not itself considered to be a Th2 cytokine (Manetti et al. 1995), it exerts several important anti-inflammatory actions, including an anti-diabetogenic role, suggested by the observation that poly I:C, an IFN-α inductor, protects NOD mice from diabetes (Rossini et al. 1995). The said protective effect should be mediated, at least in part, by the ability of IFN-α to counteract IL-1 which, in turn, is involved in the pathogenesis of type 1 diabetes in NOD mice (Nicoletti et al. 1994), up-regulating IL-1 receptor antagonist production.

Moreover, NIC is not only capable of increasing the levels of IFN-α and IL-4, but also of increasing the amount of IFN-γ, which efficiently induces MHC class I and ICAM-1 molecules (Chakrabarti et al. 1996). Interestingly, islets from diabetic NOD animals in this study show high levels of IFN-γ (P<0·001 vs NON), though these levels were significantly lower with respect to those observed in NIC-treated NOD animals (P<0·001).

High levels of IFN-γ, a proinflammatory Th1 cytokine, found in this study seem to be partly in contrast with the supposed protective role exerted by NIC. Actually, a recent study (Nicoletti et al. 1998) describes a ‘paradoxical’ anti-diabetogenic effect exerted by IFN-γ in diabetes-prone bio breeding rats. This cytokine, as indicated above, is able to induce both MHC class I and ICAM-1 expression, as other Th2 protective cytokines do, although it is known to be a proinflammatory destructive Th1 cytokine. Therefore, a revision of its action and role in type 1 diabetes development can be partly explained either as a persistence of the immune mechanisms of recognition, adhesion and cytolyis, or as a possible endocrine regeneration and/or differentiation process, as the noted expression and the BrdU positivity imply.

A further point stressed by this work concerns the expression of both Ia-b and ICAM-1 within the epithelial layer of the ducts, which has not previously been observed in younger animals (8-week-old), and, in particular, the persistence of ICAM-1 on these elements in overtly diabetic mice. These findings could be explained by the kinetics of the progression of the disease in which class II adhesion molecules are first expressed by infiltrating cells and elements of the connective tissue surrounding the ducts (including less differentiated elements such as mesenchymal cells), and, then, by the epithelial cells which become involved in the infiltration process during which mononuclear cells reach the epithelial surface. Nearing the end of infiltration in untreated NOD animals, the decrease in MHC class I and II expression is mirrored by ICAM-1. NIC has the ability to maintain an increased
expression of ICAM-1, preceded by a significant decrease in MHC class II expression.

Until now, the expression of ICAM-1 was found to be limited to the cells (endothelia or islet β cells) facing infiltrating lymphocytes, as a consequence of local accumulation of cytokines generated by infiltrated cells. For endothelia, this has been interpreted to be a contribution to the extravasation of mononuclear cells into the inflammatory sites, thus favouring the recruitment of these cells by CD8+ CTLs by means of an ICAM-1/LFA-1 interaction which takes place between islet β cells and adjacent T-lymphocytes (Yang et al. 1996). ICAM-1 positivity in pancreatic ducts is not related to facing infiltrating lymphocytes, but could be induced by locally released cytokines which have been shown to induce ICAM-1 expression, as the present study demonstrates. The apparent absence of ICAM-1 on normal adult endocrine islet and epithelial cells lining ducts, its induction by autoimmune mechanisms which take place in type 1 diabetes, its persistence in pancreatic ducts of overtly diabetic animals, and its enhancement exerted by NIC treatment suggest that the role of ICAM-1 is not only to facilitate interaction between cells of the immune and endocrine systems but also to aid interactions between these cells after the loss of insulin-containing β cells (located there) for a possible attempt at neo-histogenesis. Such a role could also be suggested by the low level of class II MHC protein in diabetic animals, which is decreased further by NIC treatment. Alternatively, NIC has been reported to induce differentiation and maturation of human pancreatic cells (Otontoski et al. 1993), a finding which may further support our results.

Moreover, despite its anti-oxidant effects, NIC does not completely protect NOD mice from diabetes development in this study. The beneficial effects of NIC are inhibition of NO synthesis, prevention of cellular NAD depletion and the scavenging of oxygen free radicals by increasing SOD, the first cellular defence against free radicals. Because NIC may prevent both cytokine-induced NO formation (Eizirik et al. 1994) and production of oxygen free radicals (Wilson et al. 1984), it would appear that combining these two effects might lead to an understanding of the cellular mechanisms by which it could exert beneficial effects against type 1 diabetes development. Although controlled in vitro conditions showed some beneficial effects, the present study confirms that in vivo NIC does not completely prevent islet β cell destruction. In fact, several previous studies have attempted to clarify the action of NIC and its ability to counteract or prevent diabetes, but the results have often been conflicting. This study shows that, although this drug has several positive actions, it does not act synergistically in completely preventing or blocking the development of the disease. The results shown by some authors seem to be in favour (Yamada et al. 1982), while others are against (Hermitte et al. 1989), a supposed anti-diabetic role for NIC. Recent trials in humans did not provide new insights, just suggesting that the drug can preserve and improve stimulated islet β cell function only in patients diagnosed after puberty (Pozzilli et al. 1995).

Acknowledgements

This work was supported by MURST (60%) and Campania Region funds. The authors are grateful to Mr Georgios Daphnis (Zoological Station ‘A Dohrn’, Naples, Italy) for technical help and to Dr J J Garland, Medical Editor, Thomas Jefferson University, Philadelphia, PA, USA, for reading the manuscript.

References


Yamada K, Miyajima E & Nonaka K 1990 Inhibition of cytokine-induced MHC class II but not class I molecule expression on mouse islet cells by niacinamide and 3-aminobenzamide. Diabetologia 39 1125–1130.


Received 29 June 1998
Accepted 20 October 1998